Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2080220578
JPRN-jRCT2080220578
Unknown
Phase 2

Paricalcitol Injection Long-term Safety Study

Abbott Japan Co., Ltd.0 sitesJuly 10, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSecondary Hyperparathyroidism

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Secondary Hyperparathyroidism
Sponsor
Abbott Japan Co., Ltd.
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 10, 2008
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Abbott Japan Co., Ltd.

Eligibility Criteria

Inclusion Criteria

  • •Aged 20 or over
  • •Subjects allocated to paricalcitol groups in the phase IIb study (dose\-response study) and completed it with good tolerability to paricalcitol injection

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
TS-FARMEV StudySolid tumors refractory to oncospecific treatment.
RPCEC00000112Center for Genetic Engineering and Biotechnology (CIGB), in Havana.
Completed
N/A
Clinical pharmacological study for safety evaluation of ephedrine alkaloids-free Ephedra Herb extract (EFE) in healthy volunteersthose who are adapted Kampo formula which include Ephedra Herb
JPRN-UMIN000022061Clinical Trial Center, Kitasato University Hospital12
Active, Not Recruiting
Phase 1
A long-term study to monitor the health status of people with cystic fibrosis who took part in a previous study with BI 3720931 (LenticlairTM-ON)Cystic fibrosisMedDRA version: 20.0Level: PTClassification code: 10011763Term: Cystic fibrosis lung Class: 100000004850Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
CTIS2023-504909-37-00Boehringer Ingelheim International GmbH27
Completed
N/A
Clinical study to investigate the long-term safety and efficacy of human cell line recombinant Factor VIII (human-cl rhFVIII) in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiency
ISRCTN90038418Octapharma AG (Switzerland)22
Recruiting
N/A
Clinical trial to evaluate safety and dose response of the C2 CryoBalloon 180 Ablation SystemBarrett's esophagus<br />Barrett's dysplasia<br />Cryoablation<br />Cryotherapy<br /><br />Barrett slokdarm<br />Barrett neoplasie<br />Cryoablatie<br />Cryotherapie
NL-OMON28028C2 Therapeutics, Inc.25